The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Pancreatic cancer: understanding and overcoming chemoresistance
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Ali, S., Ahmad, A., Banerjee, S., Padhye, S., Dominiak, K., Schaffert, J. M., Wang, Z., Philip, P. A., & Sarkar, F. H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4598 · Cited by 424
Self-citationRetractedWang, F., Xue, X., Wei, J., An, Y., Yao, J. J., Cai, H., Wu, J., Dai, C., Qian, Z., Xu, Z., et al. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605724 · Cited by 140
RetractedJemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Epithelial-Mesenchymal Transitions in Development and Disease
Thiery, J. P., Acloque, H., Huang, R. Y. J., & Nieto, M. A. (2009) · Cell · doi:10.1016/j.cell.2009.11.007 · Cited by 9,931
The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells
Mani, S. A., Guo, W., Liao, M.-J., Eaton, E. N., Ayyanan, A., Zhou, A. Y., Brooks, M., Reinhard, F., Zhang, C. C., Shipitsin, M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.027 · Cited by 8,672
Complex networks orchestrate epithelial–mesenchymal transitions
Thiery, J. P., & Sleeman, J. P. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1835 · Cited by 3,958
Targeting multidrug resistance in cancer
Szakács, G., Paterson, J. K., Ludwig, J. A., Booth-Genthe, C., & Gottesman, M. M. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1984 · Cited by 3,609 · cited 1×
“Drug resistance is classified into two categories: intrinsic ( de novo or innate) resistance and acquired resistance”
BackgroundIdentification of Pancreatic Cancer Stem Cells
Li, C., Heidt, D. G., Dalerba, P., Burant, C. F., Zhang, L., Adsay, V., Wicha, M., Clarke, M. F., & Simeone, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2030 · Cited by 3,339
Clarke, M. F., Dick, J. E., Dirks, P. B., Eaves, C. J., Jamieson, C. H. M., Jones, D. L., Visvader, J., Weissman, I. L., & Wahl, G. M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-3126 · Cited by 3,051
Hermann, P. C., Huber, S. L., Herrler, T., Aicher, A., Ellwart, J. W., Guba, M., Bruns, C. J., & Heeschen, C. (2007) · Cell Stem Cell · doi:10.1016/j.stem.2007.06.002 · Cited by 2,897
Mechanisms of Cancer Drug Resistance
Gottesman, M. M. (2002) · Annual Review of Medicine · doi:10.1146/annurev.med.53.082901.103929 · Cited by 2,643 · cited 1×
“The three most common reasons for the acquisition of drug resistance are the expression of energy-requiring transporters (which extrude chemotherapeutic drugs from the cancer cells), insensitivity to drug-induced apoptosis and the induction of drug-detoxification mechanisms”
BackgroundEMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Gupta, P. B., Onder, T. T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R. A., & Lander, E. S. (2009) · Cell · doi:10.1016/j.cell.2009.06.034 · Cited by 2,389
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs
Wellner, U., Schubert, J., Burk, U. C., Schmalhofer, O., Zhu, F., Sonntag, A., Waldvogel, B., Vannier, C., Darling, D., Hausen, A. Z., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1998 · Cited by 1,699
Targeting microRNAs in cancer: rationale, strategies and challenges
Garzon, R., Marcucci, G., & Croce, C. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3179 · Cited by 1,493
Genetic variation in microRNA networks: the implications for cancer research
Ryan, B. M., Robles, A. I., & Harris, C. C. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2867 · Cited by 1,257
Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N., & Struhl, K. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2994 · Cited by 1,115
Epithelial to Mesenchymal Transition Contributes to Drug Resistance in Pancreatic Cancer
Arumugam, T., Ramachandran, V., Fournier, K. F., Wang, H., Marquis, L., Abbruzzese, J. L., Gallick, G. E., Logsdon, C. D., McConkey, D. J., & Choi, W. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2819 · Cited by 863
Targeting the PI3K/Akt/mTOR pathway: Effective combinations and clinical considerations
LoPiccolo, J., Blumenthal, G. M., Bernstein, W. B., & Dennis, P. A. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2007.11.003 · Cited by 801
MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells
Ji, Q., Hao, X., Zhang, M., Tang, W., Yang, M., Li, L., Xiang, D., DeSano, J. T., Bommer, G. T., Fan, D., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006816 · Cited by 689
Voulgari, A., & Pintzas, A. (2009) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2009.03.002 · Cited by 671
Li, Y., VandenBoom, T. G., Kong, D., Wang, Z., Ali, S., Philip, P. A., & Sarkar, F. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1298 · Cited by 663
Self-citationThomson, S., Buck, E., Petti, F., Griffin, G., Brown, E., Ramnarine, N., Iwata, K. K., Gibson, N., & Haley, J. D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1058 · Cited by 663
The therapeutic promise of the cancer stem cell concept
Frank, N. Y., Schatton, T., & Frank, M. H. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41004 · Cited by 636
Wang, Z., Li, Y., Kong, D., Banerjee, S., Ahmad, A., Azmi, A. S., Ali, S., Abbruzzese, J. L., Gallick, G. E., & Sarkar, F. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4312 · Cited by 619
Self-citationMicroRNAs as regulators of epithelial-mesenchymal transition
Gregory, P. A., Bracken, C. P., Bert, A. G., & Goodall, G. J. (2008) · Cell Cycle · doi:10.4161/cc.7.20.6851 · Cited by 506
Giovannetti, E., Funel, N., Peters, G. J., Del Chiaro, M., Erozenci, L. A., Vasile, E., Leon, L. G., Pollina, L. E., Groen, A., Falcone, A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4467 · Cited by 457
Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma
Rasheed, Z. A., Yang, J., Wang, Q., Kowalski, J., Freed, I., Murter, C., Hong, S.-M., Koorstra, J.-B., Rajeshkumar, N. V., He, X., et al. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp535 · Cited by 437
Development and Characterization of Gemcitabine-Resistant Pancreatic Tumor Cells
Shah, A. N., Summy, J. M., Zhang, J., Park, S. I., Parikh, N. U., & Gallick, G. E. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9583-5 · Cited by 433
miR-146a Suppresses Invasion of Pancreatic Cancer Cells
Li, Y., VandenBoom, T. G., Wang, Z., Kong, D., Ali, S., Philip, P. A., & Sarkar, F. H. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2792 · Cited by 421
Self-citationSun, M., Estrov, Z., Ji, Y., Coombes, K. R., Harris, D. H., & Kurzrock, R. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-2272 · Cited by 412
Kong, D., Banerjee, S., Ahmad, A., Li, Y., Wang, Z., Sethi, S., & Sarkar, F. H. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012445 · Cited by 411
Self-citationLee, C. J., Dosch, J., & Simeone, D. M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.16.6702 · Cited by 374
Moriyama, T., Ohuchida, K., Mizumoto, K., Yu, J., Sato, N., Nabae, T., Takahata, S., Toma, H., Nagai, E., & Tanaka, M. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0592 · Cited by 342
Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications
Brown, B. D., & Naldini, L. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2628 · Cited by 336
CD44‐positive cells are responsible for gemcitabine resistance in pancreatic cancer cells
Hong, S. P., Wen, J., Bang, S., Park, S., & Song, S. Y. (2009) · International Journal of Cancer · doi:10.1002/ijc.24573 · Cited by 290
Hwang, J.-H., Voortman, J., Giovannetti, E., Steinberg, S. M., Leon, L. G., Kim, Y.-T., Funel, N., Park, J. K., Kim, M. A., Kang, G. H., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0010630 · Cited by 290
Park, J.-K., Lee, E. J., Esau, C., & Schmittgen, T. D. (2009) · Pancreas · doi:10.1097/mpa.0b013e3181ba82e1 · Cited by 287
Jimeno, A., Feldmann, G., Suárez-Gauthier, A., Rasheed, Z., Solomon, A., Zou, G.-M., Rubio-Viqueira, B., García-García, E., López-Ríos, F., Matsui, W., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0924 · Cited by 276
Dembinski, J. L., & Krauss, S. (2009) · Clinical & Experimental Metastasis · doi:10.1007/s10585-009-9260-0 · Cited by 271
Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment
Jiang, B.-H., & Liu, L.-Z. (2008) · Drug Resistance Updates · doi:10.1016/j.drup.2008.03.001 · Cited by 243
Targeting Notch signaling pathway to overcome drug resistance for cancer therapy
Wang, Z., Li, Y., Ahmad, A., Azmi, A. S., Banerjee, S., Kong, D., & Sarkar, F. H. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.06.001 · Cited by 233
Self-citationKallifatidis, G., Labsch, S., Rausch, V., Mattern, J., Gladkich, J., Moldenhauer, G., Büchler, M. W., Salnikov, A. V., & Herr, I. (2011) · Molecular Therapy · doi:10.1038/mt.2010.216 · Cited by 218
Implication of microRNAs in drug resistance for designing novel cancer therapy
Sarkar, F. H., Li, Y., Wang, Z., Kong, D., & Ali, S. (2010) · Drug Resistance Updates · doi:10.1016/j.drup.2010.02.001 · Cited by 215
Self-citationRausch, V., Liu, L., Kallifatidis, G., Baumann, B., Mattern, J., Gladkich, J., Wirth, T., Schemmer, P., Büchler, M. W., Zöller, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0066 · Cited by 209
Buck, E., Eyzaguirre, A., Barr, S., Thompson, S., Sennello, R., Young, D., Iwata, K. K., Gibson, N. W., Cagnoni, P., & Haley, J. D. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0462 · Cited by 191
Li, Y., Kong, D., Wang, Z., & Sarkar, F. H. (2010) · Pharmaceutical Research · doi:10.1007/s11095-010-0105-y · Cited by 190
Self-citationMelkamu, T., Zhang, X., Tan, J., Zeng, Y., & Kassie, F. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp208 · Cited by 158
Dietary polyphenol quercetin targets pancreatic cancer stem cells
Herr (2010) · International Journal of Oncology · doi:10.3892/ijo_00000704 · Cited by 158
Pancreatic Cancer Cells Resistant to Chemoradiotherapy Rich in “Stem-Cell-Like” Tumor Cells
Du, Z., Qin, R., Wei, C., Wang, M., Shi, C., Tian, R., & Peng, C. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-010-1340-0 · Cited by 139
Emerging roles of PDGF-D signaling pathway in tumor development and progression
Wang, Z. P., Ahmad, A., Li, Y., Kong, D., Azmi, A. S., Banerjee, S., & Sarkar, F. H. (2010) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2010.04.003 · Cited by 127
Self-citationKabashima, A., Higuchi, H., Takaishi, H., Matsuzaki, Y., Suzuki, S., Izumiya, M., Iizuka, H., Sakai, G., Hozawa, S., Azuma, T., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24349 · Cited by 114
Integrins as Novel Drug Targets for Overcoming Innate Drug Resistance
Damiano, J. S. (2002) · Current Cancer Drug Targets · doi:10.2174/1568009023334033 · Cited by 110
WANG, Y., Li, F., LUO, B., Wang, X., Sun, H., LIU, S., Cui, Y., & Xu, X. (2009) · Neoplasma · doi:10.4149/neo_2009_05_371 · Cited by 106
Mimeault, M., Johansson, S. L., Senapati, S., Momi, N., Chakraborty, S., & Batra, S. K. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.02.015 · Cited by 77
Miao, X. (2010) · Oncology Reports · doi:10.3892/or_00000774 · Cited by 45
Cited by
Broad targeting of resistance to apoptosis in cancer
Mohammad, R. M., Muqbil, I., Lowe, L., Yedjou, C., Hsu, H.-Y., Lin, L.-T., Siegelin, M. D., Fimognari, C., Kumar, N. B., Dou, Q. P., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.001 · Cited by 864
Self-citationZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance
Zhang, P., Sun, Y., & Ma, L. (2015) · Cell Cycle · doi:10.1080/15384101.2015.1006048 · Cited by 611
Pancreatic Cancer Chemoresistance to Gemcitabine
Amrutkar, M., & Gladhaug, I. (2017) · Cancers · doi:10.3390/cancers9110157 · Cited by 448
Cancer stem cells and chemoresistance: The smartest survives the raid
Zhao, J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.008 · Cited by 437
Targeting hypoxic tumor microenvironment in pancreatic cancer
Tao, J., Yang, G., Zhou, W., Qiu, J., Chen, G., Luo, W., Zhao, F., You, L., Zheng, L., Zhang, T., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01030-w · Cited by 412
Metadata
- Authors
- Wang, Z., Li, Y., Ahmad, A., Banerjee, S., Azmi, A. S., Kong, D., & Sarkar, F. H.
- Venue
- Nature Reviews Gastroenterology & Hepatology
- Published
- 2010-11-23
- Volume
- 8
- Issue
- 1
- Pages
- 27-33
- ISSN
- 1759-5045 (ISSN-L)
- 1759-5053
- OpenAlex
- W1979342940
- Cited by
- 364
- References
- 56
- FWCI
- 2.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.